Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)

This study is currently recruiting participants. (see Contacts and Locations)

Verified May 2016 by Merck Sharp & Dohme Corp.

Sponsor:
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:
NCT02622074

First received: December 2, 2015
Last updated: May 20, 2016
Last verified: May 2016
History of Changes

Purpose

The purpose of this study is to evaluate the safety, tolerability and clinical activity of pembrolizumab (MK-3475) in combination with two chemotherapy regimens as neoadjuvant treatment for participants with triple negative breast cancer (TNBC).

The primary objectives of this study are: 1) to determine the safety and tolerability and 2) to establish a recommended Phase 2 dose for the two combination regimens: 1) pembrolizumab + nab-paclitaxel followed by pembrolizumab + doxorubicin + cyclophosphamide; and 2) pembrolizumab + nab-paclitaxel + carboplatin followed by pembrolizumab + doxorubicin + cyclophosphamide, as a neoadjuvant treatments for participants with TNBC.

Condition	Intervention	Phase
Triple Negative Breast Neoplasms	Biological: Pembrolizumab Drug: Nab-paclitaxel Drug: Anthracycline Drug: Cyclophosphamide Drug: Carboplatin	Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Drug Information available for: Cyclophosphamide Paclitaxel Carboplatin Pembrolizumab

U.S. FDA Resources

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:

- Number of Participants with Dose Limiting Toxicities [Time Frame: Up to 90 days] [Designated as safety issue: Yes]

Secondary Outcome Measures:

- Number of Participants with a Pathological Complete Response [Time Frame: Up to 27 weeks] [Designated as safety issue: No]

Estimated Enrollment: 60

Study Start Date:	January 2016
Estimated Study Completion Date:	August 2017
Estimated Primary Completion Date:	August 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Pembro+Np→Pembro+A+C Participants receive pembrolizumab (pembro) intravenously (IV) PLUS nab-paclitaxel (Np) IV; followed by pembrolizumab IV PLUS anthracycline (e.g. doxorubicin) (A) IV PLUS cyclophosphamide (C) IV.	Biological: Pembrolizumab Drug: Nab-paclitaxel Drug: Anthracycline Drug: Cyclophosphamide
Experimental: Pembro+Np+Cb→Pembro+A+C Participants receive pembrolizumab (pembro) IV PLUS nab-paclitaxel (Np) IV PLUS carboplatin (Cb) IV; followed by pembrolizumab IV PLUS anthracycline (e.g. doxorubicin) (A) IV PLUS cyclophosphamide (C) IV.	Biological: Pembrolizumab Drug: Nab-paclitaxel Drug: Anthracycline Drug: Cyclophosphamide Drug: Carboplatin

Eligibility

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

- Has previously untreated, locally advanced TNBC.
- Is able to provide 2 core needle biopsies from the primary tumor at screening to the central laboratory and agrees to have a core needle biopsy after single dose pembrolizumab treatment if tumor biopsy is feasible as judged by the investigator.
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has adequate organ function.
- Females of childbearing potential must be willing to use adequate contraception for the course of the study through 12 months after the last dose of study drug for participants receiving cyclophosphamide and through 6 months after the last dose of study drug for participants who do not receive cyclophosphamide.

Exclusion Criteria:

- Has evidence of metastatic breast cancer, concurrent bilateral invasive breast cancer, or inflammatory breast cancer.
- Has another malignancy within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative surgery, or in situ cervical cancer.
- Has received prior chemotherapy, targeted therapy, radiation therapy, immunotherapy that targets immune checkpoints, co-stimulatory or co-inhibitory pathways for T cell receptors within the past 12 months.
- Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
- Has received a live vaccine within 30 days of the first dose of study drug.
- Has an active autoimmune disease that has required systemic treatment in past 2 years.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- Has a known history of Human Immunodeficiency Virus (HIV).
- Has known active Hepatitis B or Hepatitis C.
- Has evidence of active, non-infectious pneumonitis.
- Has history of pneumonitis requiring treatment with steroids or history of interstitial lung disease.
- Has an active infection requiring systemic therapy.
- Has significant cardiovascular disease, such as: History of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA class III or IV
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.
- Has a known hypersensitivity to the components of the study drug or its analogs.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02622074

Contacts

Contact: Toll Free Number 1-888-577-8839

Locations

Denmark

Merck Sharp & Dohme — **Recruiting**
Glostrup, Denmark
Contact: Gert Andersen 45 44824475

Finland

MSD Finland Oy — **Recruiting**
Espoo, Finland
Contact: Kaisa Elomaa 358 20 7570300

Germany

Merck Sharp & Dohme GmbH — **Recruiting**
Haar, Germany
Contact: German Medical Information Center 49 800 673 673 673

Korea, Republic of

MSD Korea LTD — **Recruiting**
Seoul, Korea, Republic of, 4130
Contact: Jongho Ahn 82-2-331-2000 2015

Singapore

Merck Sharp & Dohme (I.A.) Corp — **Recruiting**
Singapore, Singapore
Contact: Cesar Recto 632 784 9500

Spain

Merck Sharp and Dohme de Espana S.A. — **Recruiting**
Madrid, Spain
Contact: Joaquin Mateos Chacon (0034) 913210600

Sweden

MSD Sweden — **Recruiting**
Stockholm, Sweden
Contact: Tryggve Ljung 46 (0)70 545 28 66

United Kingdom

Merck Sharp & Dohme Ltd. — **Recruiting**
Hoddesdon, United Kingdom
Contact: Mark Toms +44 (0) 1992 452475

Sponsors and Collaborators

Merck Sharp & Dohme Corp.

Investigators

Study Director: Medical Director Merck Sharp & Dohme Corp.

More Information

Responsible Party:	Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:	NCT02622074 History of Changes
Other Study ID Numbers:	3475-173 2015-002405-11
Study First Received:	December 2, 2015
Last Updated:	May 20, 2016
Health Authority:	United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
PD1
PD-1
PDL1
PD-L1
Triple Negative Breast Cancer

Additional relevant MeSH terms:

Breast Neoplasms	Immunologic Factors
Triple Negative Breast Neoplasms	Physiological Effects of Drugs
Neoplasms by Site	Antirheumatic Agents
Neoplasms	Antineoplastic Agents, Alkylating

Breast Diseases	Alkylating Agents
Skin Diseases	Molecular Mechanisms of Pharmacological Action
Cyclophosphamide	Antineoplastic Agents
Pembrolizumab	Myeloablative Agonists
Carboplatin	Antineoplastic Agents, Phytogenic
Paclitaxel	Tubulin Modulators
Albumin-Bound Paclitaxel	Antimitotic Agents
Immunosuppressive Agents	Mitosis Modulators

ClinicalTrials.gov processed this record on July 06, 2016